• September 20, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019. “The approval ofmore...
  • September 9, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that its scientists presented positive efficacy data for the company’s investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La. Zoetis is developing a triple combination product containing sarolaner, moxidectin and pyrantel that is administered orally once a month as a preventative for heartworm disease and to treat and control ticks, fleas,more...
  • August 15, 2019
    PARSIPPANY, NEW JERSEY, AUGUST 15, 2019 – Today, Zoetis, the world’s leading animal health company, announced that it will expand its portfolio of products and services for horses with the Stablelab® hand-held, point-of-care diagnostic blood test, which provides veterinarians critical information related to equine inflammation in 10 minutes.The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), which is a major, acute phase protein produced by the liver thatmore...
  • August 14, 2019
    PARSIPPANY, N.J. & BUELLTON, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Platinum Performance, a privately-held nutrition-focused animal heath company, after fulfilling all closing requirements. The acquisition was first announced on July 22 and financial terms of the transaction are not being disclosed. “We are pleased to welcome the Platinum Performance team to Zoetis and together expand on the success of their high-quality,more...
  • July 31, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis, the leading global animal health company, today announced it is teaming up with actress and animal lover Kate Walsh1 to help dogs feel their best and stay on their A-Game. The Show Us Your Dog’s A-Game campaign brings awareness to how skin diseases and allergies affect a dog’s well-being, and encourages pet owners to visit their veterinarians who can provide the right treatment to bring back their dogs’ A-Games. Timed with the inaugural “Itchy Petmore...
  • July 22, 2019
    PARSIPPANY, N.J. & BUELLTON, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced it has entered into an agreement to acquire Platinum Performance, a privately held, nutrition-focused animal health company. Platinum’s premium nutritional product formulas and unique approach to the field of scientific wellness for horses, dogs and cats will further strengthen and diversify Zoetis’ portfolio in the equine and petcare markets. Financial terms of the transaction are not beingmore...
  • September 14, 2018
    Zoetis today announced that the U.S. Department of Agriculture (USDA) has granted an expanded indication for Cytopoint®, a novel monoclonal antibody (mAb) therapy for the treatment of allergic dermatitis in dogs. Cytopoint is the first mAb therapy licensed to treat allergic as well as atopic dermatitis, an indication for which it was fully licensed by the USDA in 2016. Administered every four to eight weeks, one injection of Cytopoint works by targeting and neutralizing interleukin-31 (IL-31more...
  • December 12, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis today announced the launch of Vanguard® CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against two strains of the virus known to be circulating in the U.S., CIV H3N2 and CIV H3N8. CIV is a severe and highly contagious respiratory infection that has caused many serious disease outbreaks in 38 states across the country.1 The United States Department ofmore...
  • April 26, 2017
    ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use. Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets andmore...
  • April 5, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the leading global animal health company, today announced that music and television star Nick Lachey* is teaming up with the company to launch Your Animal Instinct , a program to help your dog put its best paw forward this spring. Your Animal Instinct aims to help pet owners understand when their dog’s itching may be due to an allergy-related skin condition – and what they can do about it.more...